Universal Vision Biotechnology Co (3218.TWO) Stock Price

Universal Vision Biotechnology Co Price

CLOSED
134.50TWD-2.00 (-1.48 %)
Market closed

Over the last 19 years Universal Vision Biotechnology Co grew revenue by 14.2% annually, reaching 4.20 B TWD. Earnings per share have grown at 32.1% per year over the last 5 years. For Universal Vision Biotechnology Co, the net margin of 24.8% is up versus 22.6% a few years ago. At today's price the dividend yield works out to roughly 5.58%. The payout ratio is around 50% of earnings. The dividend has grown at 14.5% per year over the past 3 years. The consensus 12-month price target for Universal Vision Biotechnology Co is 172.38 TWD, about 28.2% above where the stock trades today. Of 9 analysts, 0 rate the stock a buy — an overall Sell consensus. The stock trades about 9% above its 52-week low.

Universal Vision Biotechnology Co stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Universal Vision Biotechnology Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Universal Vision Biotechnology Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Universal Vision Biotechnology Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Universal Vision Biotechnology Co Stock Price History
DateUniversal Vision Biotechnology Co Price
8/25/2026134.50 TWD
8/24/2026136.50 TWD
8/21/2026137.00 TWD
8/20/2026137.00 TWD
8/19/2026134.50 TWD
8/18/2026133.50 TWD
8/17/2026135.50 TWD
8/14/2026134.00 TWD
8/13/2026136.50 TWD
8/12/2026144.00 TWD
8/11/2026146.00 TWD
8/10/2026144.50 TWD
8/7/2026142.50 TWD
8/6/2026140.00 TWD
8/5/2026139.50 TWD
8/4/2026136.00 TWD
8/3/2026133.50 TWD
7/31/2026135.00 TWD
7/30/2026133.50 TWD
7/29/2026132.50 TWD
7/28/2026136.00 TWD
7/27/2026139.00 TWD
7/24/2026137.00 TWD
7/23/2026136.50 TWD
7/22/2026138.50 TWD
7/21/2026139.00 TWD
7/20/2026135.50 TWD
7/17/2026134.00 TWD
7/16/2026139.50 TWD
7/15/2026138.50 TWD
7/14/2026138.50 TWD
7/13/2026140.00 TWD
7/10/2026141.00 TWD
7/9/2026141.00 TWD
7/8/2026141.00 TWD
7/7/2026145.50 TWD
7/6/2026144.00 TWD
7/3/2026141.50 TWD
7/2/2026136.50 TWD
7/1/2026138.00 TWD
6/30/2026137.00 TWD
6/29/2026135.50 TWD
6/26/2026130.50 TWD
6/25/2026133.50 TWD
6/24/2026133.50 TWD
6/23/2026133.50 TWD
6/22/2026135.00 TWD
6/18/2026133.50 TWD
6/17/2026134.00 TWD
6/16/2026133.00 TWD
6/15/2026137.00 TWD
6/12/2026135.00 TWD
6/11/2026131.00 TWD
6/10/2026132.50 TWD
6/9/2026134.50 TWD
6/8/2026131.50 TWD
6/5/2026135.00 TWD
6/4/2026135.50 TWD
6/3/2026137.00 TWD
6/2/2026138.00 TWD
6/1/2026140.00 TWD
5/29/2026138.00 TWD
5/28/2026130.50 TWD
5/27/2026130.00 TWD
5/26/2026128.50 TWD
5/25/2026129.00 TWD
5/22/2026131.00 TWD
5/21/2026130.00 TWD
5/20/2026128.50 TWD
5/19/2026129.00 TWD
5/18/2026127.50 TWD
5/15/2026127.00 TWD
5/14/2026129.00 TWD
5/13/2026130.50 TWD
5/12/2026133.50 TWD
5/11/2026135.50 TWD
5/8/2026132.50 TWD
5/7/2026134.00 TWD
5/6/2026135.00 TWD
5/5/2026136.50 TWD
5/4/2026138.00 TWD
4/30/2026136.00 TWD
4/29/2026139.00 TWD
4/28/2026126.50 TWD
4/27/2026123.50 TWD
4/24/2026125.50 TWD
4/23/2026128.50 TWD
4/22/2026130.50 TWD
4/21/2026130.00 TWD
4/20/2026129.00 TWD
4/17/2026132.00 TWD
4/16/2026132.00 TWD
4/15/2026131.50 TWD
4/14/2026130.50 TWD
4/13/2026129.50 TWD
4/10/2026130.00 TWD
4/9/2026131.00 TWD
4/8/2026131.50 TWD
4/7/2026132.50 TWD
4/2/2026132.00 TWD
4/1/2026136.00 TWD
3/31/2026132.50 TWD
3/30/2026131.50 TWD
3/27/2026131.00 TWD
3/26/2026131.50 TWD
3/25/2026138.50 TWD
3/24/2026140.50 TWD
3/23/2026138.00 TWD
3/20/2026140.50 TWD
3/19/2026140.00 TWD
3/18/2026143.00 TWD
3/17/2026143.50 TWD
3/16/2026144.00 TWD
3/13/2026142.50 TWD
3/12/2026140.50 TWD
3/11/2026144.50 TWD
3/10/2026141.00 TWD
3/9/2026139.50 TWD
3/6/2026140.50 TWD
3/5/2026133.00 TWD
3/4/2026130.50 TWD
3/3/2026134.50 TWD
3/2/2026136.50 TWD
2/26/2026136.50 TWD
2/25/2026136.00 TWD
2/24/2026136.00 TWD
2/23/2026138.00 TWD
2/11/2026135.50 TWD
2/10/2026141.50 TWD
2/9/2026140.00 TWD
2/6/2026138.50 TWD
2/5/2026142.50 TWD
2/4/2026141.00 TWD
2/3/2026140.50 TWD
2/2/2026142.00 TWD
1/30/2026143.00 TWD
1/29/2026147.00 TWD
1/28/2026149.00 TWD
1/27/2026151.00 TWD
1/26/2026151.00 TWD
1/23/2026152.50 TWD
1/22/2026152.00 TWD
1/21/2026148.50 TWD
1/20/2026151.00 TWD
1/19/2026150.00 TWD
1/16/2026148.00 TWD
1/15/2026149.50 TWD
1/14/2026149.50 TWD
1/13/2026149.00 TWD
1/12/2026149.50 TWD
1/9/2026148.00 TWD
1/8/2026148.00 TWD
1/7/2026145.50 TWD
1/6/2026144.50 TWD
1/5/2026144.00 TWD
1/2/2026146.00 TWD
12/31/2025146.00 TWD
12/30/2025145.00 TWD
12/29/2025147.50 TWD
12/26/2025145.00 TWD
12/24/2025146.00 TWD
12/23/2025146.50 TWD
12/22/2025145.00 TWD
12/19/2025144.50 TWD
12/18/2025141.00 TWD
12/17/2025141.50 TWD
12/16/2025140.50 TWD
12/15/2025141.00 TWD
12/12/2025141.00 TWD
12/11/2025140.50 TWD
12/10/2025143.00 TWD
12/9/2025144.00 TWD
12/8/2025147.00 TWD
12/5/2025147.50 TWD
12/4/2025151.00 TWD
12/3/2025149.50 TWD
12/2/2025150.50 TWD
12/1/2025150.50 TWD
11/28/2025152.50 TWD
11/27/2025152.00 TWD
11/26/2025153.50 TWD
11/25/2025149.00 TWD
11/24/2025146.00 TWD
11/21/2025144.50 TWD
11/20/2025149.00 TWD
11/19/2025146.50 TWD
11/18/2025148.00 TWD
11/17/2025152.00 TWD
11/14/2025157.50 TWD
11/13/2025155.50 TWD
11/12/2025145.00 TWD
11/11/2025139.00 TWD
11/10/2025136.50 TWD
11/7/2025135.50 TWD
11/6/2025139.50 TWD
11/5/2025140.00 TWD
11/4/2025141.50 TWD
11/3/2025144.00 TWD
10/31/2025143.00 TWD
10/30/2025142.50 TWD
10/29/2025143.50 TWD
10/28/2025142.50 TWD
10/27/2025146.50 TWD
10/23/2025145.00 TWD
10/22/2025146.00 TWD
10/21/2025142.50 TWD
10/20/2025140.00 TWD
10/17/2025142.50 TWD
10/16/2025142.00 TWD
10/15/2025142.00 TWD
10/14/2025142.00 TWD
10/13/2025143.50 TWD
10/9/2025147.50 TWD
10/8/2025149.00 TWD
10/7/2025152.00 TWD
10/3/2025154.50 TWD
10/2/2025154.00 TWD
10/1/2025157.00 TWD
9/30/2025159.00 TWD
9/26/2025159.50 TWD
9/25/2025161.00 TWD
9/24/2025161.50 TWD
9/23/2025162.50 TWD
9/22/2025163.00 TWD
9/19/2025163.00 TWD
9/18/2025168.50 TWD
9/17/2025170.00 TWD
9/16/2025168.00 TWD
9/15/2025170.00 TWD
9/12/2025169.50 TWD
9/11/2025169.00 TWD
9/10/2025178.50 TWD
9/9/2025179.00 TWD
9/8/2025180.50 TWD
9/5/2025179.00 TWD
9/4/2025179.00 TWD
9/3/2025178.00 TWD
9/2/2025177.50 TWD
9/1/2025177.50 TWD
8/29/2025181.50 TWD
8/28/2025181.50 TWD
8/27/2025180.00 TWD
8/26/2025179.00 TWD
Access this data via the Eulerpool API
Get Free API Key

Universal Vision Biotechnology Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
2.05 B TWD
613.08 M TWD
483.21 M TWD
Jan 1, 2021
2.63 B TWD
776.59 M TWD
595.43 M TWD
Jan 1, 2022
3.49 B TWD
1.11 B TWD
850.53 M TWD
Jan 1, 2023
4.08 B TWD
1.34 B TWD
1.05 B TWD
Jan 1, 2024
4.23 B TWD
1.40 B TWD
1.06 B TWD
Jan 1, 2025
4.20 B TWD
1.38 B TWD
1.04 B TWD
Jan 1, 2026 (e)
4.25 B TWD
1.64 B TWD
1.14 B TWD
Jan 1, 2027 (e)
4.44 B TWD
1.60 B TWD
1.21 B TWD

Universal Vision Biotechnology Co Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 26, 2026, 2:31 AM
 
REVENUEB TWD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB TWD
EBITB TWD
EBIT MARGIN%
NET INCOMEB TWD
NET INCOME GROWTH%
DIV.TWD
DIV. GROWTH%
SHARESM
201220132014201520162017201820192020202120222023202420252026e2027e
0.770.850.991.011.071.081.191.422.052.633.494.084.234.204.254.44
-7.7011.2115.832.635.720.9310.3518.7644.7828.1532.8016.833.58-0.571.124.45
323.60290.97251.2155.7255.1354.2554.1957.6261.7162.1861.2259.9759.9159.0459.0459.04
2.482.482.480.570.590.590.650.821.271.642.142.452.532.482.512.62
–0.090.100.090.110.130.140.250.610.781.111.341.401.381.641.60
–10.439.929.0710.5411.8311.6417.4229.8629.4931.8532.7833.1132.7538.5336.01
–0.090.100.080.090.120.160.240.480.600.851.051.061.041.141.21
––17.44-19.8012.3531.8734.1747.83102.9423.1942.8622.941.82-2.079.505.70
––––––––––5.005.667.007.507.758.88
–––––––––––13.2023.677.143.3314.58
84.8084.8084.8084.8084.8084.8084.8076.1276.1276.1284.9285.0484.8084.8084.8084.80
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Universal Vision Biotechnology Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Universal Vision Biotechnology Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Universal Vision Biotechnology Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Universal Vision Biotechnology Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Universal Vision Biotechnology Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Universal Vision Biotechnology Co stock margins

The Universal Vision Biotechnology Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Universal Vision Biotechnology Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Universal Vision Biotechnology Co.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
61.72 %
29.86 %
23.54 %
Jan 1, 2021
62.18 %
29.51 %
22.62 %
Jan 1, 2022
61.24 %
31.86 %
24.34 %
Jan 1, 2023
59.98 %
32.79 %
25.60 %
Jan 1, 2024
59.91 %
33.12 %
25.18 %
Jan 1, 2025
59.05 %
32.76 %
24.80 %
Jan 1, 2026 (e)
59.05 %
38.54 %
26.84 %
Jan 1, 2027 (e)
59.05 %
36.01 %
27.17 %

Universal Vision Biotechnology Co Stock Revenue, EBIT, Earnings per Share

The Universal Vision Biotechnology Co earnings per share therefore indicates how much revenue Universal Vision Biotechnology Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
26.97 TWD
8.05 TWD
6.35 TWD
Jan 1, 2021
34.57 TWD
10.20 TWD
7.82 TWD
Jan 1, 2022
41.15 TWD
13.11 TWD
10.02 TWD
Jan 1, 2023
48.01 TWD
15.74 TWD
12.29 TWD
Jan 1, 2024
49.86 TWD
16.51 TWD
12.56 TWD
Jan 1, 2025
0.00 TWD
0.00 TWD
0.00 TWD
Jan 1, 2026 (e)
50.18 TWD
19.32 TWD
13.47 TWD
Jan 1, 2027 (e)
52.42 TWD
18.86 TWD
14.24 TWD

Universal Vision Biotechnology Co business model & stock analysis

Universal Vision Biotechnology Co Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Universal Vision Biotechnology Co historical P/E ratio, EBIT multiple, and P/S ratio

Universal Vision Biotechnology Co annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Universal Vision Biotechnology Co shares outstanding

The number of shares of Universal Vision Biotechnology Co was 84.8 M in 2025. This indicates how many shares Universal Vision Biotechnology Co is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
76.12 M Stocks
Jan 1, 2021
76.12 M Stocks
Jan 1, 2022
84.92 M Stocks
Jan 1, 2023
85.04 M Stocks
Jan 1, 2024
84.80 M Stocks
Jan 1, 2025
84.80 M Stocks
Jan 1, 2026 (e)
84.80 M Stocks
Jan 1, 2027 (e)
84.80 M Stocks

Universal Vision Biotechnology Co stock splits

In Universal Vision Biotechnology Co's history, there have been no stock splits.

Universal Vision Biotechnology Co Dividend History

5 years of dividend payments · 3 consecutive increases

YearAnnual DividendYoY ChangePayments
20267.75TWDYTD—1×
Mar 26, 20267.75TWD↑ 3.3%1/1
20257.50TWD↑ 7.1%1×
Mar 26, 20257.50TWD↑ 7.1%1/1
20247.00TWD↑ 23.7%1×
20235.66TWD↑ 13.2%1×
20225.00TWD—1×

Universal Vision Biotechnology Co dividend history and estimates

In 2025, Universal Vision Biotechnology Co paid a dividend amounting to 7.50 TWD. Dividend means that Universal Vision Biotechnology Co distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2022
5.00 TWD
0.00 TWD
Jan 1, 2023
5.66 TWD
0.00 TWD
Jan 1, 2024
7.00 TWD
0.00 TWD
Jan 1, 2025
7.50 TWD
0.00 TWD
Jan 1, 2026
7.75 TWD
0.00 TWD
Jan 1, 2027 (e)
0.00 TWD
8.88 TWD

Universal Vision Biotechnology Co dividend payout ratio

In 2025, Universal Vision Biotechnology Co had a payout ratio of 49.81%. The payout ratio indicates the percentage of the company's profits that Universal Vision Biotechnology Co distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2020
49.81 %
Jan 1, 2021
49.81 %
Jan 1, 2022
44.85 %
Jan 1, 2023
48.82 %
Jan 1, 2024
55.75 %
Jan 1, 2025
49.81 %
Jan 1, 2026 (e)
57.54 %
Jan 1, 2027 (e)
62.37 %

Current Universal Vision Biotechnology Co forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
0.00 % (0)
Hold
55.56 % (5)
Sell
44.44 % (4)
12M Price Target
172.38
Last Price
134.50
Currency
TWD
12M Return Potential
28.16 %
LTM Return
0 %

Universal Vision Biotechnology Co Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
5/11/20243.84TWD-1.21 BTWD-2024 Q1
3/27/20243.44TWD-1.09 BTWD-2023 Q4

Universal Vision Biotechnology Co shareholder structure

% Name
22.75142%
Lin (Pi Jung)
Lin (Pi Jung)
9.00142%
Jui Li Investment Co., Ltd.
Jui Li Investment Co., Ltd.
8.87040%
QunYi Development Enterprise Co., Ltd.
QunYi Development Enterprise Co., Ltd.
3.87158%
Core Capital Co., Ltd.
Core Capital Co., Ltd.
3.27786%
Zhuang (Ming Lang)
Zhuang (Ming Lang)
3.00401%
XinShi Investments Co., Ltd.
XinShi Investments Co., Ltd.

Universal Vision Biotechnology Co Beneficial Ownership Filings (SEC 13D/G)

Free Float
50.9%
Float Shares
-
Shares Outstanding
-

Universal Vision Biotechnology Co Executives and Management Board

13 members · avg. age 54 · 33 % women

KL

Mr. Kenneth Lu

General Manager

13.75 M TWD

Management

PL

Mr. Pi-Jung Lin

Chief Technology Officer, Director · since 2001

3.91 M TWD
SL

Ms. Su-Ping Lien

Head of Corporate Governance, Manager of Sustainable Development Office

–
YS

Ms. Yu-Chiao Sun

Head of Finance & Accounting

–
CL

Mr. Chun-Chieh Liu

Senior Head of Ophthalmology Business Division · since 2018

–

Board of Directors

SO

Ms. Shu-Fang Ou

Chairman of the Board · since 2003

5.07 M TWD
TC

Mr. Tsan-Der Chou

Director

2.88 M TWD
SW

Ms. Su-Hei Weng

Director

2.88 M TWD
MH

Mr. Min-Chih Hsiao

Independent Director

2.88 M TWD
VL

Mr. Vincent Liu

Independent Director

2.88 M TWD
YY

Mr. Yun-Hua Yang

Independent Director

2.88 M TWD

Frequently asked questions about Universal Vision Biotechnology Co

Analysts currently set an average price target of 172.38 TWD for the Universal Vision Biotechnology Co stock (median: 172.38 TWD), implying +28.2 % versus the latest price. The consensus is based on 9 analyst ratings.

Universal Vision Biotechnology Co Analyst Price Targets 2026

9 analysts currently rate the Universal Vision Biotechnology Co stock: 0 recommend buying, 5 holding and 4 selling. For 2026, analysts expect Universal Vision Biotechnology Co to generate revenue of 4.25 B TWD and earnings per share of 13.46 TWD.

Universal Vision Biotechnology Co Analyst Price Targets 2026

Converted at the current exchange rate, the Universal Vision Biotechnology Co share trades at 3.62 EUR (134.50 TWD).

No history available for Universal Vision Biotechnology Co.

The expected revenue of Universal Vision Biotechnology Co is 4.25 B TWD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Universal Vision Biotechnology Co is 1.14 B TWD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Universal Vision Biotechnology Co is currently 9.99. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Universal Vision Biotechnology Co stock.

The price-to-sales ratio (P/S) of Universal Vision Biotechnology Co is currently 2.68. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Universal Vision Biotechnology Co stock.

The Eulerpool Quality Score for Universal Vision Biotechnology Co is 7/10.

The ISIN of Universal Vision Biotechnology Co is TW0003218004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Universal Vision Biotechnology Co is 3218.TWO. The ticker symbol is used to trade Universal Vision Biotechnology Co shares on the stock exchange.

Over the past 12 months, Universal Vision Biotechnology Co paid a dividend of 7.50 TWD . This corresponds to a dividend yield of about 5.58 %. For the coming 12 months, Universal Vision Biotechnology Co is expected to pay a dividend of 8.88 TWD.

The current dividend yield of Universal Vision Biotechnology Co is 5.58 %.

Universal Vision Biotechnology Co pays a dividend, distributed in the months of , , , .

Universal Vision Biotechnology Co paid dividends every year for the past 4 years.

For the upcoming 12 months, dividends amounting to 8.88 TWD are expected. This corresponds to a dividend yield of 6.60 %.

Universal Vision Biotechnology Co is assigned to the 'Health' sector.

In the year 2025, Universal Vision Biotechnology Co distributed 7 TWD as dividends.

The dividends of Universal Vision Biotechnology Co are distributed in TWD.

All fundamentals and in-depth analysis of Universal Vision Biotechnology Co

Our stock analysis for Universal Vision Biotechnology Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Universal Vision Biotechnology Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Universal Vision Biotechnology Co Stock
Universal Vision Biotechnology Co Revenue→
Universal Vision Biotechnology Co Stock
Universal Vision Biotechnology Co Net Income→
Universal Vision Biotechnology Co Stock
Universal Vision Biotechnology Co P/E→
Universal Vision Biotechnology Co Stock
Universal Vision Biotechnology Co P/S→
Universal Vision Biotechnology Co Stock
Universal Vision Biotechnology Co EBIT→
Universal Vision Biotechnology Co Stock
Universal Vision Biotechnology Co Dividend→
Universal Vision Biotechnology Co Stock
Universal Vision Biotechnology Co Directors Dealings→
Universal Vision Biotechnology Co Stock
Universal Vision Biotechnology Co Stocks→
Universal Vision Biotechnology Co Stock
Universal Vision Biotechnology Co Market capitalization→
Universal Vision Biotechnology Co Stock
Universal Vision Biotechnology Co Debt→
Universal Vision Biotechnology Co Stock
Universal Vision Biotechnology Co Liabilities→
Universal Vision Biotechnology Co Stock
Universal Vision Biotechnology Co Equity→
Universal Vision Biotechnology Co Stock
Universal Vision Biotechnology Co AAQS→
Universal Vision Biotechnology Co Stock
Universal Vision Biotechnology Co Employees→
Universal Vision Biotechnology Co Stock
Universal Vision Biotechnology Co ROE→
Universal Vision Biotechnology Co Stock
Universal Vision Biotechnology Co ROA→
Universal Vision Biotechnology Co Stock
Universal Vision Biotechnology Co ROCE→
Universal Vision Biotechnology Co Stock
Universal Vision Biotechnology Co News→
Universal Vision Biotechnology Co Stock
Universal Vision Biotechnology Co Analyst Price Targets→

Health Stocks

Universe PharmaceuticalsUniversal Health ServicesUpHealthUniversal Health International Group HoldingUpstream BioUniversal BiosensorsUrogen PharmaUnivecUrtesteUnitedHealth GroupUS Physical TherapyUnited TherapeuticsAll Stocks A–Z →